Roche’s injectable monoclonal antibody Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) has been approved by the US Food and Drug Administration (FDA) to treat both relapsing and primary ...

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics's Enhanze drug ...

Credit: Genentech Ocrevus Zunovo is supplied in a single-dose vial containing 920mg of ocrelizumab and 23,000 units hyaluronidase per 23mL. Ocrevus Zunovo is a combination of ocrelizumab, a ...

OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: ...

Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq) can cause mild to serious side effects. More common side effects include respiratory infections (upper and lower). If ...

Ocrelizumab 920mg, hyaluronidase-ocsq 23000 Units; per 23mL; soln for SC inj; preservative-free. Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do ...

Genentech, a member of the Roche Group, announced today that the United States Food and Drug Administration has approved Ocrevus Zunovo™ for the treatment of relapsing multiple sclerosis and primary ...

Roche has received the Food and Drug Administration’s clearance for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with Halozyme's Enhanze drug delivery technology. The medication is indicated ...

OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's office This approval is backed by a decade of proven ...